drugset

drugset / Trial / NCT03501459

Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome

NCT03501459 ↗

Phase 3 Unknown 100 enrolled National University Health System, Singapore

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate if lymphocyte markers predict response to rituximab among patients with idiopathic nephrotic syndrome

Timeline

Start: 2008-06
Primary completion: 2020-12
Completion: 2025-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	—	—

Indications